Biology:Glycoprotein 130

From HandWiki
Revision as of 11:34, 11 February 2024 by MainAI5 (talk | contribs) (fixing)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Mammalian protein found in Homo sapiens


A representation of the 3D structure of the protein myoglobin showing turquoise α-helices.
Generic protein structure example

Glycoprotein 130 (also known as gp130, IL6ST, IL6R-beta or CD130) is a transmembrane protein which is the founding member of the class of tall cytokine receptors. It forms one subunit of the type I cytokine receptor within the IL-6 receptor family. It is often referred to as the common gp130 subunit, and is important for signal transduction following cytokine engagement. As with other type I cytokine receptors, gp130 possesses a WSXWS amino acid motif that ensures correct protein folding and ligand binding. It interacts with Janus kinases to elicit an intracellular signal following receptor interaction with its ligand. Structurally, gp130 is composed of five fibronectin type-III domains and one immunoglobulin-like C2-type (immunoglobulin-like) domain in its extracellular portion.[1][2]

Characteristics

The members of the IL-6 receptor family all complex with gp130 for signal transduction. For example, IL-6 binds to the IL-6 Receptor. The complex of these two proteins then associates with gp130. This complex of 3 proteins then homodimerizes to form a hexameric complex which can produce downstream signals.[3] There are many other proteins which associate with gp130, such as cardiotrophin 1 (CT-1), leukemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), oncostatin M (OSM), and IL-11.[4] There are also several other proteins which have structural similarity to gp130 and contain the WSXWS motif and preserved cysteine residues. Members of this group include LIF-R, OSM-R, and G-CSF-R.

Loss of gp130

gp130 is an important part of many different types of signaling complexes. Inactivation of gp130 is lethal to mice.[5] Homozygous mice who are born show a number of defects including impaired development of the ventricular myocardium. Haematopoietic effects included reduced numbers of stem cells in the spleen and liver.

Signal transduction

gp130 has no intrinsic tyrosine kinase activity. Instead, it is phosphorylated on tyrosine residues after complexing with other proteins. The phosphorylation leads to association with JAK/Tyk tyrosine kinases and STAT protein transcription factors.[6] In particular, STAT-3 is activated which leads to the activation of many downstream genes. Other pathways activated include RAS and MAPK signaling.

Interactions

Glycoprotein 130 has been shown to interact with:

References

  1. "Molecular cloning and expression of an IL-6 signal transducer, gp130". Cell 63 (6): 1149–1157. 1990. doi:10.1016/0092-8674(90)90411-7. PMID 2261637. 
  2. "Crystal structure of a cytokine-binding region of gp130". EMBO J 17 (6): 1665–1674. 1998. doi:10.1093/emboj/17.6.1665. PMID 9501088. 
  3. "IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase". Science 260 (5115): 1808–1810. 1993. doi:10.1126/science.8511589. PMID 8511589. Bibcode1993Sci...260.1808M. 
  4. "Interleukin-6 family of cytokines and gp130". Blood 86 (4): 1243–1254. 1995. doi:10.1182/blood.V86.4.1243.bloodjournal8641243. PMID 7632928. 
  5. "Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders". Proc. Natl. Acad. Sci. USA 93 (1): 407–411. 1996. doi:10.1073/pnas.93.1.407. PMID 8552649. Bibcode1996PNAS...93..407Y. 
  6. "Cytokine signal transduction". Cell 76 (2): 253–262. 1994. doi:10.1016/0092-8674(94)90333-6. PMID 8293462. 
  7. "Vav is associated with signal transducing molecules gp130, Grb2 and Erk2, and is tyrosine phosphorylated in response to interleukin-6". FEBS Lett. 401 (2–3): 133–7. January 1997. doi:10.1016/s0014-5793(96)01456-1. PMID 9013873. 
  8. "An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells". Oncogene 21 (3): 460–74. January 2002. doi:10.1038/sj.onc.1205100. PMID 11821958. 
  9. 9.0 9.1 "Transmembrane domain of gp130 contributes to intracellular signal transduction in hepatic cells". J. Biol. Chem. 272 (49): 30741–7. December 1997. doi:10.1074/jbc.272.49.30741. PMID 9388212. 
  10. "Mapping of a region within the N terminus of Jak1 involved in cytokine receptor interaction". J. Biol. Chem. 276 (40): 37451–8. October 2001. doi:10.1074/jbc.M106135200. PMID 11468294. 
  11. "Structural requirements of the interleukin-6 signal transducer gp130 for its interaction with Janus kinase 1: the receptor is crucial for kinase activation". Biochem. J. 361 (Pt 1): 105–11. January 2002. doi:10.1042/0264-6021:3610105. PMID 11742534. 
  12. "A functional role of the membrane-proximal extracellular domains of the signal transducer gp130 in heterodimerization with the leukemia inhibitory factor receptor". Eur. J. Biochem. 269 (11): 2716–26. June 2002. doi:10.1046/j.1432-1033.2002.02941.x. PMID 12047380. 
  13. "Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation". J. Biol. Chem. 271 (51): 32635–43. December 1996. doi:10.1074/jbc.271.51.32635. PMID 8999038. 
  14. 14.0 14.1 "SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130". J. Biol. Chem. 278 (1): 661–71. January 2003. doi:10.1074/jbc.M210552200. PMID 12403768. 
  15. "Signal transduction of IL-6, leukemia-inhibitory factor, and oncostatin M: structural receptor requirements for signal attenuation". J. Immunol. 165 (5): 2535–43. September 2000. doi:10.4049/jimmunol.165.5.2535. PMID 10946280. 
  16. "Shc mediates IL-6 signaling by interacting with gp130 and Jak2 kinase". J. Immunol. 158 (9): 4097–103. May 1997. doi:10.4049/jimmunol.158.9.4097. PMID 9126968. 
  17. "The transcription co-repressor TLE1 interacted with the intracellular region of gpl30 through its Q domain". Mol. Cell. Biochem. 232 (1–2): 163–7. March 2002. doi:10.1023/A:1014880813692. PMID 12030375. 

Further reading

External links